News and Announcements
Shivom Strikes Strategic Alliance with Genetic Technologies Limited (ASX: GTG)
- Published March 20, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Genetic Technologies Limited a diversified molecular diagnostics company; provider of BREVAGenplus: registered, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, has announced its plans to collaborate with Project Shivom.
The partnership aims to build on the technologies of GTG Labs and Project Shivom’s reach. Dr Paul Kasian, Genetic Technologies’ Chairman commented: “The Board is excited about the opportunity to collaborate with Project Shivom on its unique blockchain platform. Where the formal terms are agreed with Project Shivom, access to such a large database of genomic data would allow GTG to utilize its SNP based risk assessment technologies.”
To read the full ASX announcement made by GTG please click here.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
